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Abstract 
Purpose. Little data are available regarding the relation of left ventricular (LV) mechanical dyssynchrony to 
remodelling after acute myocardial infarction (MI) and stem-cell therapy. We evaluated the one-year time-course of 
both LV mechanical dyssynchrony and remodelling in patients enrolled in the BONAMI trial, a randomized, 
multicenter controlled trial assessing cell therapy in patients with reperfused MI. 
Methods. Patients with acute MI and ejection fraction (EF) ≤ 45% were randomized to cell therapy or to control, and 
underwent thallium single-photon emission computed tomography (SPECT), radionuclide angiography and 
echocardiography at baseline, 3 month and 1 year. Eighty-three patients with a comprehensive 1-year follow-up were 
included. LV dyssynchrony was assessed by the standard deviation (SD) of the LV phase histogram using 
radionuclide angiography. Remodelling was defined as a 20% increase in LV end-systolic volume index (LVESVI) 
at 1 year.  
Results. At baseline, LVEF, wall motion score index and perfusion defect size were significantly impaired in the 43 
patients (52%) with LV remodelling (all p<0.001), without significant increase in LV mechanical dyssynchrony. 
During follow-up, there was a progressive increase in LV SD (P=0.01). Baseline independent predictors of LV 
remodelling were perfusion SPECT defect size (p=0.001), LVEF (p=0.01) and a history of hypertension (p=0.043). 
Bone marrow cell therapy did not affect the time-course of LV remodelling and dyssynchrony.  
Conclusions. LV remodelling 1 year after reperfused MI is associated with progressive LV dyssynchrony and is 
related to baseline infarct size and ejection fraction, without impact of cell therapy on this process.  
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4 
Introduction 
The improvements in treatment of acute myocardial infarction (MI), aimed to restore persistent myocardial 
perfusion, preserve myocyte integrity and prevent left ventricular (LV) dysfunction, have resulted in a better early 
survival. However, with more patients surviving the initial stage of AMI, post-infarction LV remodelling occurs in a 
relevant proportion of patients [1]. Although the remodelling process tends to restore stroke volume despite a 
depressed ejection fraction, ventricular dilation is associated with a poor long term clinical outcome [2]. Infarct size, 
infarct-related artery patency, anterior location, LV end-systolic volume and microvascular obstruction are clinical 
predictors of LV remodelling. Recent results suggested that early LV dyssynchrony has an additional detrimental 
impact on LV function [3] and could predict the occurrence of LV remodelling [4,5]. However, it remains unclear 
whether LV dyssynchrony observed soon after acute MI is independently associated with LV remodelling.  
In the setting of irreversible myocyte loss following an acute myocardial infarction, and given the poor endogenous 
regenerative capacity of the heart, stem cell therapy has emerged as a unique opportunity for cardiac repair. 
However, a meta-analysis of randomized control trials demonstrated a poor long term improvement of left 
ventricular function after stem cell therapy, showing only a 3% increase in left ventricular ejection fraction which 
remains the most frequently assessed surrogate endpoint [6]. 
Accordingly, this study was conducted to assess the determinants of ventricular remodelling in patients with 
reperfused myocardial infarction and left ventricular dysfunction eligible for stem cell therapy. To achieve this goal, 
we assessed the 1-year time course of ventricular remodelling in a cohort of patients prospectively included in the 
BONAMI trial, a study dedicated to evaluate the effect of bone marrow-derived cells therapy on myocardial viability 
[7].  
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Material and methods 
Patient population. The BONAMI study was a randomized, multicentre controlled trial assessing cell therapy in 
patients with acute MI. Screening criteria were: age 18–75 years, a successful percutaneous coronary intervention 
(PCI) with bare metal stent implantation performed on the culprit lesion during the 24 h after the onset of symptoms, 
and LVEF < 50% assessed by echocardiography. The culprit artery was defined as an occluded artery or by a severe 
stenosis secondary to superimposed thrombus. Randomization criteria were defined as follows: LVEF ≤45% 
assessed by RNA and absence of myocardial viability in at least 2/17 contiguous segments by SPECT. Main 
exclusion criteria were: age >75 years; previous myocardial infarction; patient instability after myocardial infarction; 
cardiac disease except ischemic heart disease; multivessel coronary artery disease; need for coronary 
revascularization in the future; pulmonary edema and cardiogenic shock; advanced renal or hepatic failure; non-
cardiac disease adversely affecting prognosis; coagulopathy, thrombocytopenia, and leukopenia. As previously 
described [7], 101 patients met the inclusion criteria and were randomized to cell therapy (n=52) or to control 
(n=49). After inclusion, patients underwent Thallium perfusion SPECT, equilibrium radionuclide angiography and 
echocardiography at baseline, 3 month and 1 year follow-up. In the present study, the population consisted with 83 
patients with a comprehensive follow-up at 1 year. The ethics review board of Nantes University Hospital approved 
the protocol, and the study was conducted in accordance with the Declaration of Helsinki. All subjects gave informed 
consent. 
Radionuclide equilibrium angiography. Planar equilibrium radionuclide angiography (RNA) was performed in all 
patients and left (LVEF) and right ejection fraction (RVEF) calculated using a count based method [8]. The mean 
phase angle and phase standard deviation were derived from the phase histograms. Left ventricular mechanical 
synchrony was assessed as the standard deviation of the left ventricular phase histogram (LV SD). Interventricular 
contractile synchrony was calculated as the absolute difference between LV and RV mean phase angles (RV-LV). 
Results were expressed in milliseconds (ms). 
Myocardial perfusion imaging. Myocardial perfusion SPECT was acquired 15 minutes and 3-4 hours after a rest 
injection of thallium-201 (1.5 MBq/kg). SPECT data were analyzed using a 17-segment division of the left ventricle 
[9] by consensus of 2 experienced observers blinded from any clinical data. Infarct extent was calculated using an 
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automated software and expressed as the percentage of LV showing a thallium uptake <60%. This latter criterion 
was applied on early images at the acute phase, and on redistribution images at follow-up, according to previous 
results showing that within the first week after myocardial infarction, early thallium imaging better reflects 
myocardial viability and functional recovery [10]. 
Echocardiography. All echocardiography examinations were recorded and analyzed off-line by experienced 
investigators blinded from any clinical data. Left ventricular end-diastolic and end-systolic diameter (LVEDD and 
LVESD) were measured in the parasternal long axis view. Left ventricular volumes (biplane modified Simpson rule) 
and ejection fraction were measured from four-chamber apical views and volumes were indexed to body surface area 
(LVEDVI and LVESVI) [11]. Wall motion score index (WMSI) was calculated using a 17-segment model [9] and a 
4-point grading system from 1 (normal) to 4 (dyskinetic). Pulmonary artery systolic pressure (PASP) was determined 
using the modified Bernouilli equation. Tissue Doppler profiles were recorded at the medial and lateral mitral 
annulus from the apical 4-chamber view. Systolic tissue velocity (S), early diastolic (E’) and late diastolic (A’) tissue 
velocities were recorded, and the septal and lateral E/E’ ratio were calculated. 
Statistical analysis. Results were expressed as mean ± SD or number (percentages), as appropriate. Comparisons 
between groups were performed with Student’s t tests or χ2 tests. Correlations were presented with Pearson 
coefficient (r, p-value). Adjusted correlations between variables were assessed by linear regression analysis. Logistic 
regression analysis was used to analyze the determinants of LV mechanical dyssynchrony or remodelling and LVEF 
impairment (odds ratio with 95% CI). These parameters were: clinical characteristics, MI treatment, radionuclide and 
echocardiographic parameters. To analyze repeated measures over time (imaging parameters), we used mixed 
models and adjusted Tukey tests. All models were adjusted by the treatment allocated (control or bone marrow cell 
therapy) and interactions were tested (only p-values <0.05 were maintained).  
Left ventricular remodelling is a complex process and involves different pathophysiological mechanisms over time 
[12]. To account for this phenomenon, the predictive value of potential predictors of late remodelling was analyzed 
both at baseline and 3 month after myocardial infarction. The presence of LV remodelling was defined as a relative 
increase of at least 20% in LVESVI between baseline and 1-year follow-up. In addition, indexed end-systolic 
volumes were analyzed as a continuous variable and predictors of ESVI at 1-year follow-up were determined. All 
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analyses were performed using SAS 9.1 statistical software (SAS Institute, Cary, NC, USA). A p-value <0.05 was 
considered statistically significant. 
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Results 
Baseline data. Eighty-three patients with a comprehensive follow-up at 1 year were included. During primary PCI, 
TIMI flow grade III was obtained in 78 patients (99%). The patients included in the study had large myocardial 
infarctions, as demonstrated by high peak troponin levels and a large perfusion SPECT defect resulting in left 
ventricular dilation and systolic dysfunction (see Table 1). Medical therapy was not different between patients 
groups (see supplemental data). The delay between myocardial infarction and baseline investigations was as follows: 
planar RNA, 4±2 days; thallium SPECT, 5±3 days; echocardiography, 7±2 days. 
LV remodelling at 1-year follow-up. A preliminary statistical analysis of 3-month and 1-year functional results 
showed no difference between both patients groups (control group and group receiving cardiac cell therapy) for 
LVESVI and LVEF. Therefore, all patients were further analysed together, independently of cardiac cell therapy. 
During the first year after MI, there was a progressive impairment of global left ventricular function, with a 
significant increase in both end-diastolic (p<0.0001) and end-systolic (p<0.0001) volume indexes (see table 2). 
Along with LV dilation, both inter- and intra-ventricular dyssynchrony progressively increased during follow-up, 
particularly in patients with LV remodelling (see Figure 1). Similarly, there was also a progressive left atrial 
remodelling process. The treatment regimen allocated (control or bone marrow cell therapy) did not modify the time-
course of LV remodelling and dyssynchrony. 
Using univariate linear regression, the baseline parameters associated with ESVI measured at 1-year follow-up were: 
LV SD (p= 0.03), LVEF, LVESVI, LVEDVI, WMSI and thallium SPECT defect size (all p values < 0.0001). 
Among the parameters measured 3 months after MI, those associated with ESVI measured at 1-year follow-up 
included LVESVI, LVEDVI, LVEF, WMSI, LVEDDI, LVESDI, thallium SPECT defect size, and LV SD (all p 
values < 0.0001). Using multivariate analysis, the independent predictors of ESVI at 1-year follow-up were, at 
baseline: LVEF (p< 0.0001) and thallium SPECT defect size (p= 0.002), and at 3 months: ESVI (p< 0.0001) and 
WMSI (p= 0.035).  
The study population was divided into 2 groups of patients with (n= 43, 52%) and without LV remodelling (n=40, 
48%). At baseline (see table 1), patients with LV remodelling at 1 year showed a larger infarct size (documented by 
9 
increased peak troponin level and  perfusion SPECT defect size), and an impairment of LV function demonstrated by 
decreased WMSI and LVEF compared to patients without LV remodelling. In addition, they were more likely to 
have a culprit lesion on the left anterior descending coronary artery and a history of hypertension. At 1-year follow-
up, LV SD correlated to RNA LVEF (r= -0.64. p<0.0001), LVESVI (r= 0.54, p<0.0001), LVEDVI (r= 0.55, 
p<0.0001), perfusion SPECT defect (r=0.33, p=0.003) and peak troponin (r= 0.24, p= 0.037). No significant 
differences in LV mechanical dyssynchrony parameters were observed between the two groups of patients.  
Univariate predictors of LV remodelling at 1-year follow-up are depicted in table 3. Using logistic multivariate 
analysis (N=79), independent predictors at baseline were RNA LVEF (OR: 0.138, 95% confidence interval : 0.053-
6.686, p= 0.01), perfusion SPECT defect size (OR: -0.073, 95% confidence interval : 0.022-11.390, p= 0.001) and 
hypertension (OR: 0.607, 95% confidence interval : 0.300-4.094, p= 0.04). Among the parameters assessed at 3-
month follow-up, LVEDD (OR: 1.133, 95% confidence interval: 1.017-1.23, p= 0.02) was an independent predictor 
of remodelling. 
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Discussion 
Despite encouraging initial results, cell therapy hardly demonstrated a significant but modest improvement of left 
ventricular function in humans. There is a lack of data analyzing the determinants of left ventricular remodelling in 
patients receiving cell therapy that may help to enhance the efficacy of regenerative strategies. The relationship 
between early LV asynchrony observed after an acute MI and late LV remodelling is still controversial and has not 
been investigated in this population. The main findings of this study can be summarized as follows: 1) One half of 
the patients included in the BONAMI trial exhibited significant remodelling at 1-year after acute myocardial 
infarction despite an optimal management; 2) at baseline, the independent predictors of remodelling included LVEF, 
perfusion SPECT defect and a history of hypertension; 3) dyssynchrony at baseline was not predictive of 
remodelling in this population; and finally 4) ventricular remodelling was not significantly impacted by bone marrow 
cell therapy.  
Incidence of left ventricular remodelling. Although LV function is commonly used as a surrogate endpoint for 
efficacy of cell therapy, the incidence of ventricular remodelling at 1 year after MI remains unknown in patients 
prospectively enrolled in clinical trials [6,13–16]. During follow-up, 52% of our study population demonstrated a 
significant remodelling of the left ventricle, which is higher than previously observed after acute myocardial 
infarction. In a recent study, Mollema et al. [17] reported a significant remodelling (defined as an absolute increase 
in LVESV ≥ 15%) in 20% of patients. Using the end-diastolic volume index as a marker of remodelling, Giannuzzi 
et al. [18] found severe remodelling in 16% of patients. These latter studies investigated non selected patients with a 
relatively preserved LV function (mean LVEF from 46 to 48%) compared to our study. In patients with larger MI, 
Bolognese et al. [1] reported LV remodelling in a higher proportion (30%) of patients. The high incidence of 
ventricular remodelling in our study is likely due to the enrolment of selected patients with LV dysfunction and large 
myocardial infarcts. 
Dyssynchrony and predictors of left ventricular remodelling. Cardiac remodelling after MI is associated with poor 
event-free survival [1]. White et al. [19] early showed that end-systolic volume was the most powerful predictor of 
death after myocardial infarction. On the other hand, left ventricular recovery after successful primary PCI is 
associated with a better long-term prognosis [2]. Primary PCI and pharmacologic therapies targeting the rennin-
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angiotensin system and neuro-hormonal activation have shown a beneficial impact on remodelling [20–23]. 
However, the early identification of patients at high risk of remodelling after MI is of paramount importance.  
Recent data suggested a relationship between remodelling and dyssynchrony. Using 2D speckle tracking, Mollema et 
al. [17] evaluated 194 consecutive patients admitted with an acute myocardial infarction treated by primary PCI. In 
this study, dyssynchrony showed the strongest correlation with the incidence of remodelling at 6-month follow-up, 
even after adjustment for the peak level of troponin, hypertension, baseline LVESV and baseline LVEDV. In a series 
of 47 patients, Zhang et al. [4] demonstrated that patients with remodelling (defined in this study as an increase in 
LVESV ≥ 10% at 1 year) had a higher extent of early dyssynchrony and infarct size assessed by contrast-enhanced 
cardiac magnetic resonance. However, they also found that dyssynchrony was correlated with WMSI, ESV, EDV, 
LVEF and infarct size at baseline. Nucifora et al. [3] further demonstrated that patients with mechanically reperfused 
infarction and LVEF ≤ 45% had a higher extent of dyssynchrony and increased infarct size using contrast 
echocardiography. Finally, Turan et al. [24] found a sensitivity of 73% of dyssynchrony for predicting remodelling 
after a first MI treated successfully by PCI. 
In the present study, we found no difference in terms of dyssynchrony at baseline between patients with and without 
remodelling. The BONAMI trial enrolled patients with large infarcts (mean infarct size = 31% of the LV) and LV 
dysfunction (mean LVEF: 39%), two factors that are correlated to ventricular dyssynchrony [25]. As a consequence, 
even patients without LV remodelling at follow-up had dyssynchrony at baseline. Moreover, the culprit artery was 
the LAD in all but four patients in our study population. Previous findings demonstrated that in patients with anterior 
infarction dyssynchrony is increased compared to patients with inferior infarction, even in patients with normal QRS 
duration [25,26]. Thus, assessing patients with anterior infarction might also contribute to the low predictive value of 
phase analysis, as anterior segments have a higher contribution to observed dispersion with respect to inferior and 
posterior segments. Nucifora et al. [27] reported temporal evolution of LV dyssynchrony after reperfused myocardial 
infarction and observed that dyssynchrony changes were associated with changes in LVEF. In the present study, 
although there was a progressive increase of dyssynchrony over time, baseline inter- or intra-ventricular mechanical 
delays was not predictive of ventricular remodelling. The use of the planar technique, that analyses dyssynchrony on 
a projection of the overall cardiac volume, may have contributed to the low predictive value of phase analysis in this 
study. It is likely that planar imaging does not accurately discriminate the respective contributions of the infarct zone 
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and the remote territory. The assessment of left ventricular mechanical contraction as determined by phase analysis 
of ECG-gated myocardial perfusion SPECT has been recently proposed to overcome this issue [28]. Henneman et al. 
[29] demonstrated that the response to cardiac resynchronization therapy is related to the presence of LV 
dyssynchrony assessed by phase analysis from gated myocardial perfusion SPECT, including in patients with 
ischemic cardiomyopathy. These results suggest that the usage of SPECT techniques could be more appropriate for 
the assessment of left ventricular dyssynchrony in patients with large myocardial scars. 
Infarct size and viability are strong predictors of clinical outcome after myocardial infarction. The prognostic value 
of infarct size has been early established [30] using myocardial perfusion SPECT. The extent of infarct-zone viability 
was reported as inversely correlated with further changes in end-diastolic volumes at 6 months [31]. Moreover, 
perfusion SPECT performed within 1 month after the acute phase of infarction could predict ventricular enlargement 
with a high accuracy [32,33]. Our results demonstrated that the independent predictors of a significant remodelling in 
this population were baseline LVEF and infarct size assessed by rest perfusion SPECT.  
Impact of cell therapy on left ventricular remodelling. Recently, the BONAMI trial [7] demonstrated that 
intracoronary autologous bone marrow cells (BMC) administration to patients with decreased LVEF after MI was 
associated with a 3-month improvement of myocardial viability. Moreover, LVEF significantly increased by 4.3% 
(p = 0.001) in the control group and 3.3% (p = 0.009) in the BMC group between baseline and 3 months, without 
difference for LVEF at 3 months between the two groups. There was no significant difference as well between 
patients groups in end-diastolic and end-systolic left ventricular volume. Several meta-analyses established that the 
improvement of LVEF and ESV in favour of stem-cell therapy is significant but modest (approximately 3-4% 
increase for LVEF, and 5-10 ml decrease for ESV), with a high degree of statistical heterogeneity in the 
comparisons. A dose-response relationship [6,13,16] was found between injected cell volume and LVEF changes, as 
well as a significant impact of intramuscular cell administration and low baseline LVEF [14,34]. In the present study, 
an intracoronary injection of BMC performed after a reperfused acute MI in addition to an optimal state-of-the-art 
pharmacological therapy did not significantly impact on left ventricular remodelling at 1-year follow-up.  
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Conclusion 
Patients with large myocardial infarction that resulted in early left ventricular dysfunction are at high risk of 
ventricular remodelling at 1-year follow-up. Baseline rest perfusion SPECT defect (i.e. infarct size) and left 
ventricular function but not LV dyssynchrony were predictive of remodelling in this population. Finally, 
intracoronary injection of bone marrow cells did not significantly impact on cardiac remodelling. 
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Figure 1. Time course of left ventricular dyssynchrony according to left ventricular remodelling, at baseline, M3, 
and M12. *p≤ 0.05  
 
patients  without LV remodeling Pa tie nts with LV r emodeling Tota l
0
10
20
30
40
50
60
70
80
90
100
110
Baseline
M3
M12
*
*
LV
 
SD
 
(m
s)
 
 
 
21 
Tables 
Table 1. Baseline characteristics of patients without vs. with left ventricular remodelling 
 
All subjects  
(n=83) 
No remodelling  
(n=40) 
remodelling  
(n=43) 
p-value 
 
Clinical characteristics at baseline     
Age (mean±SD) 55.3±11.3 55.1±12.3 55.6±10.5 NS. 
BMC group % (n) 54 (45) 45 (18) 63 (27) NS 
Male gender % (n) 88 (73) 95 (38) 81 (35) NS 
Hypertension % (n) 37 (31) 25 (10) 49 (21) 0.030 
Hyperlipidemia % (n) 43 (36) 38 (15) 49 (21) NS 
Diabetes % (n) 22 (18) 23 (9) 21 (9) NS 
Current smoker % (n) 54 (45) 53 (21) 56 (24) NS 
QRS duration (ms) 89.8±17.1 90.0±17.7 89.6±16.7 NS 
Peak troponin level (µg/L) 212.6±227.5 157.3±152.1 260.0±269.2 0.039 
Time to revascularization (<12h) % (n) 73 (61) 73 (29) 74 (32) NS 
Infarct-related artery (LAD) % (n) 95 (79) 90 (36) 100 (43) 0.050 
TIMI flow 2-3 after PCI % (n) 99 (78) 100 (38) 98 (40) NS 
22 
Radionuclide parameters     
Perfusion SPECT Defect size % (n) 31.1±16.3 24.6±15.0 37.1±15.2 <0.0001 
RNA LVEF (%) 37.3±8.1 40.0±7.6 34.9±7.9 0.005 
RNA RVEF (%) 46.6±10.2 45.8±9.5 47.2±10.9 NS 
LV SD (ms) 75.6±24.4 72.1±24.9 78.7±23.8 NS 
LV-RV delay (ms) 24.7±52.8 15.7±50.6 32.8±54.0 NS 
Echocardiographic parameters     
LVEDVI (ml/m2)  57.9±14.9 59.1±14.4 56.7±15.3 NS 
LVESVI (ml/m2)  35.8±12.1 35.1±10.6 36.5±13.4 NS 
LVEF (%) 38.9±7.6 41.3±6.5 36.8±8.0 0.006 
WMSI 2.4±0.3 2.3±0.3 2.5±.3 0.001 
E/E’ septal ratio 12.1±4.5 12.1±4.4 12.1±4.6 NS 
E/E’ lateral ratio 10.3±5.6 10.7±4.5 9.9±6.4 NS 
Systolic PAP (mmHg)  31.5±10 31.2±9.4 31.7±10.8 NS 
 
BP indicates blood pressure; BMC, bone marrow cell; CAD, coronary artery disease; LAD, left anterior descending 
coronary artery; PCI, percutaneous coronary intervention; MI, myocardial infarction; ACE, angiotensin-converting 
enzyme; RNA, radionuclide angiography; LVEF, left ventricular ejection fraction; RVEF, right ventricular ejection 
23 
fraction; LV, left ventricle; RV, right ventricle; SD, standard deviation of the phase histogram; LVEDVI, left 
ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; WMSI, wall motion 
score index; PAP, pulmonary artery pressure. 
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Table 2. Time course of imaging parameters  
  Baseline 3 months 1 year Global p-value 
RNA LVEF (%) 37±8.5§/** 40±10.3 39±10.7 0.0014 
RNA RVEF (%) 46.3±10.1** 48.5±9.1 48.7±8.9 0.0375 
Perfusion Defect size (%) 30.6±16‡/§§ 23.8±13 26.6±16.6 <0.0001 
LV SD (ms) 75.1±24** 76.8±36.7 85.5±37.9 0.0101 
LV-RV delay (ms) 24.6±53.8‡/§§ 14.2±42.3‡‡ 33.5±45 0.0122 
LVEDVI 57.5±14.4‡/‡‡ 68.1±21.4 71.6±25.5 <0.0001 
LVESVI 35.7±11.7‡/‡‡ 42±19 44.7±21.7 <0.0001 
LVEDD 27±3.4†/‡‡ 28.3±3.2 28.9±3.6 <0.0001 
LVESD 18.9±3.6†/‡‡ 20.6±3.5 21.4±4.1 <0.0001 
WMSI 2.4±0.3§ 2.3±0.4 2.3±0.4 0.002 
Left atrial diastolic diameter 19.7±2.8†/** 20.8±2.7 20.5±2.7 0.0007 
Left atrial volume index 28.8±10* 33.8±11.3§§ 41.1±22 <0.0001 
E/E’ septal ratio 11.9±4.4 12.1±5.4 13.1±5.9 NS 
E/E’ lateral ratio 10.1±5.3 9.3±4.2 10±6.2 NS 
25 
Systolic PAP (mmHg) 31.5±9.8 32.4±9.7 33.8±9.7 NS 
 
*p< 0.05, §p< 0.01, †p< 0.001 and ‡p < 0.0001 vs. 3 months;  
**p< 0.05, §§p< 0.01 and ‡‡p < 0.0001 vs. 1 year 
RNA, indicates radionuclide angiography; LVEF, left ventricular ejection fraction; RVEF, right ventricular ejection 
fraction; SD, standard deviation of the phase histogram; LVEDVI, left ventricular end-diastolic volume index; 
LVESVI, left ventricular end-systolic volume index; LVEDD, left ventricular end-diastolic diameter; LVESD, left 
ventricular end-systolic diameter; WMSI, wall motion score index; PAP, pulmonary artery pressure. 
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Table 3. Univariate logistic regression analysis of baseline and 3-month predictors of left ventricular remodelling at 
1-year follow-up 
  OR 95% CI p-value 
Baseline parameters    
RNA LVEF 0.92 0.86-0.98 0.009 
Echo LVEF 0.92 0.86-0.98 0.009 
WMSI 16.62 2.84-97.28 0.002 
LVEDVI 0.99 0.96-1.02 NS 
LVESVI 1.01 0.97-1.05 NS 
Perfusion SPECT defect size 1.06 1.02-1.09 0.001 
Peak troponin level 1.00 1.00-1.01 0.05 
Cell therapy (control vs. BMC) 0.49 0.20-1.17 NS 
HTA (no vs. yes) 2.86 1.13-7.27 0.03 
Non critical stenoses on non culprit arteries 0.798 0.259-2.458 NS 
3-months parameters    
RNA LVEF 0.91 0.86-0.96 0.001 
Echo LVEF 0.91 0.86-0.96 0.001 
27 
WMSI 21.87 4.67-102.4 <0.0001 
LVEDVI 1.03 1.00-1.05 0.03 
LVESVI 1.05 1.01-1.08 0.007 
Perfusion SPECT defect size 1.06 1.02-1.11 0.003 
LVEDD 1.10 1.02-1.20 0.02 
LVESD 1.07 0.99-1.14 NS 
RNA indicates radionuclide angiography; LVEF, left ventricular ejection fraction; WMSI, wall motion score index ; 
LVESVI, left ventricular end-systolic volume index; LVEDVI, left ventricular end-diastolic volume index; SPECT, 
single photon emission computed tomography; LVEDD, left ventricular end-diastolic diameter; LVESV, left 
ventricular end-systolic diameter.  
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Supplemental data: Medical therapy at discharge 
 
All subjects  
(n=83) 
No remodelling  
(n=40) 
remodelling  
(n=43) 
p-value 
 
Aspirin % (n) 99 (82) 100 (40) 98 (42) NS 
Clopidogrel % (n) 100 (83) 100 (40) 100 (43) - 
Beta-blockers % (n) 94 (78) 98 (39) 91 (39) NS 
ACE inhibitors % (n) 92 (76) 93 (37) 91 (39) NS 
Angiotensin II receptor % (n) 4 (3) 3 (1) 5 (2) NS 
Statins % (n) 100 (83) 100 (40) 100 (43) - 
Diuretics % (n) 49 (41) 40 (16) 58 (25) NS 
Aldosterone antagonists % (n) 27 (22) 20 (8) 33 (14) NS 
Anticoagulants % (n) 47 (39) 38 (15) 56 (24) NS 
 
